"Sermorelin vs HGH" compares two things that are often sold to the same person for the same reason but work in opposite ways. HGH replaces growth hormone; sermorelin asks the pituitary to make more of its own. One has current US labels and placebo-controlled adult trials with body-composition results; the other has a discontinued children's label and two small adult trials that mostly found no change. And between them sits a federal criminal statute that explains much of why the second is sold more freely than the first.
This page sets out the two records side by side, with sources and dates. Sermorelin's own results are covered in full on our sermorelin results page and its side effects on our sermorelin side effects page; this page does not restate them beyond what the comparison needs. Nothing here is a recommendation; growth hormone treatment belongs with an endocrinologist.
Side by side
| HGH (somatropin) | Sermorelin | |
|---|---|---|
| What it is | Growth hormone itself, 191 amino acids, made recombinantly | First 29 amino acids of growth-hormone-releasing hormone |
| How it acts | Replaces GH directly; works without a pituitary | Signals the pituitary to release its own GH |
| Feedback | Bypasses the body's control of GH release | Still subject to it (somatostatin, IGF-1 feedback) |
| US labels now | Current (e.g., Genotropin, August 2026 label) | None — GEREF discontinued |
| Approved uses | Children: GHD, Prader-Willi, SGA, Turner, idiopathic short stature. Adults: GHD | Formerly: children's GHD (treatment) and a pituitary test (diagnostic) |
| Adult body-composition trials | Six placebo-controlled trials, 172 adults with GHD, 6 months | Two small trials in older adults without GHD (11 and 19 people) |
| Adult result | More lean mass, less fat and waist vs placebo | No change in weight or DEXA fat; lean mass up in men only in the longer trial |
| Federal distribution rule | 21 U.S.C. § 333(e): unauthorised distribution is a felony | Not named in that provision |
HGH: what the label says it does
Somatropin is the growth hormone molecule, made by recombinant DNA. Genotropin's US label (DailyMed, August 2026 version, read 17 October 2026) lists five children's indications and one adult one: "adults with growth hormone deficiency", with the diagnosis confirmed by a growth-hormone stimulation test in most cases.
Its adult evidence is set out in the label's clinical-studies section: six randomised trials in 172 adults with growth hormone deficiency, 85 on Genotropin and 87 on placebo for a six-month double-blind period, then open treatment for up to 24 months. At six months, "lean body mass, total body water, and lean/fat ratio increased while total body fat mass and waist circumference decreased" compared with placebo, and the changes held with continued treatment. Bone mineral density fell at six months and returned to baseline by twelve. Those are effects in people whose bodies were not making growth hormone — the label's population, not healthy adults.
The label's warnings are long because the drug has been used widely for decades: increased mortality in acute critical illness; reports of sudden death in children with Prader-Willi syndrome who were severely obese or had breathing problems; possible unmasking of diabetes; intracranial hypertension, usually in the first eight weeks; serious allergic reactions; and, in adults, fluid retention. Among 1,145 adults with growth hormone deficiency in its trials, the label states that most adverse events "consisted of mild to moderate symptoms of fluid retention, including peripheral swelling, arthralgia, pain and stiffness of the extremities".
Sermorelin: what its record holds
Sermorelin was approved in the US as GEREF (EMD Serono): a diagnostic ampule (NDA 019863, approved 28 December 1990) and a treatment vial for children's growth hormone deficiency (NDA 020443, approved 26 September 1997). Drugs@FDA lists both as discontinued, with FDA's determination that they were not withdrawn for safety or effectiveness reasons — the finding compounding pharmacies rely on to prepare it now. Its labelled result was height in children: in the GEREF international trial, mean growth rate in 86 analysed children rose from 4.1 to 8.0 cm a year at six months (Thorner 1996, as set out on our sermorelin results page).
The adults now offered sermorelin by clinics are a different population. The two adult trials of sermorelin-class GHRH in older people, both 1997, are the nearest evidence:
| Trial | People | Length | Body-composition result |
|---|---|---|---|
| Vittone et al., Metabolism (PMID 9005976) | 11 men aged 64–76 | 6 weeks | No change in weight, BMI, waist-to-hip ratio or DEXA fat and muscle; 2 of 6 strength measures improved |
| Khorram et al., JCEM (PMID 9141536) | 19 adults aged 55–71 | 16 weeks | IGF-1 rose within 2 weeks, then drifted back toward baseline; lean mass rose in men only; weight unchanged |
These people did not have diagnosed growth hormone deficiency, and the trials were far smaller and shorter than somatropin's. No trial has compared sermorelin with somatropin in adults.
The mechanism difference, and what it predicts
Sermorelin can only release growth hormone that the pituitary has, and the body's brakes still work: somatostatin from the hypothalamus and rising IGF-1 both damp further release. That is why its effect has a ceiling — and why in the 16-week trial IGF-1 drifted back down even as dosing continued. It also means sermorelin does little where the pituitary itself is damaged, a common cause of adult growth hormone deficiency.
Somatropin has no such ceiling: the dose sets the level. That is what makes it work in deficiency and what makes its warnings section necessary — the label tells prescribers to monitor the response and adjust the dose, because nothing in the body will do it for them. Neither mechanism makes one "natural" and the other not; they answer different clinical problems.
The law that separates them
Growth hormone has its own provision in federal drug law. Under 21 U.S.C. § 333(e) (read 17 October 2026), whoever "knowingly distributes, or possesses with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized" by FDA "and pursuant to the order of a physician" faces up to 5 years in prison, or 10 years if the offence involves someone under 18. Anti-ageing, energy and body-composition goals in adults without diagnosed deficiency are not among the authorised uses on the labels.
The provision names human growth hormone. Sermorelin is a different molecule, and compounding pharmacies prepare it under the rules for discontinued-but-not-withdrawn drugs. That legal asymmetry — not a demonstrated equivalence in effect — is the context for clinics offering sermorelin to adults who could not lawfully be given HGH for the same purpose. Whether a particular arrangement is lawful is a question for a lawyer, not for this page.
What the record does not contain
- Any head-to-head trial of sermorelin against somatropin in adults.
- Any adult sermorelin trial in people with diagnosed growth hormone deficiency.
- Any trial of either drug showing benefit for "anti-ageing" in healthy adults.
- Any current FDA-approved sermorelin product.
How sermorelin compares with the other growth-hormone-releasing peptides is on our CJC-1295 vs sermorelin and ipamorelin vs sermorelin pages, and the approved drug in the class with a body-composition result, tesamorelin, on our tesamorelin results page. What each molecule is lives in Peptide Lexicon's sermorelin entry.
Sources and dates
Read 17 October 2026: DailyMed SPL for Genotropin (setid ffebf88b…, August 2026 version), indications, contraindications, warnings, adverse reactions, pharmacodynamics and clinical-studies sections; 21 U.S.C. § 333(e) via Cornell's Legal Information Institute. GEREF application details (Drugs@FDA, read 23 September and 6 October 2026), the Thorner 1996, Vittone 1997 and Khorram 1997 trial figures are as read and cited on our sermorelin pages, with dates given there.